Role of Thrombin Activatable Fibrinolysis Inhibitor in Endocrine and Cardiovascular Disorders

E-ISSN： 2212-3334|2|1|57-61

ISSN： 1872-2148

Source： Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol.2, Iss.1, 2008-01, pp. : 57-61

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Role of Thrombin Activatable Fibrinolysis Inhibitor in Endocrine and Cardiovascular Disorders: An Update

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol. 6, Iss. 3, 2012-09 ,pp. : 210-217

Bentham Science Publishers

Access to resources Recommend Favorite

Evaluation of Two Recombinant Plasminogen Activators in Massive Pulmonary Embolism Model and Potato Carboxypeptidase Inhibitor (PCI) role in Inhibition of Thrombin Activatable Fibrinolysis Inhibitor TAFIa in Lungs

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol. 2, Iss. 1, 2008-01 ,pp. : 45-56

Bentham Science Publishers

Access to resources Recommend Favorite

Patented Novelties in Immunoisolation for the Treatment of Endocrine Disorders

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol. 4, Iss. 1, 2010-01 ,pp. : 1-9

Bentham Science Publishers

Access to resources Recommend Favorite

Role of Galectins in Allergic Disorders

Recent Patents on Inflammation & Allergy Drug Discovery, Vol. 10, Iss. 1, 2016-04 ,pp. : 2-12

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial (Thematic Issue: Endocrine Disorders and Cognitive Function in the Elderly)

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol. 10, Iss. 1, 2016-10 ,pp. : 2-3

Bentham Science Publishers

Access to resources Recommend Favorite